The Cochrane review by Bouvain et al. [145] included one RCT that compared outcomes for IOL ≥38 weeks (n = 100) versus EM (until 42 weeks) (n = 100) for pregnant women with diabetes (either type I or type II, or GDM) treated with insulin [153]. The gene discussed is INS; the disease is gestational diabetes.